These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 26892970)

  • 21. Strategies to Overcome Residual Risk During Statins Era.
    Cho KI; Yu J; Hayashi T; Han SH; Koh KK
    Circ J; 2019 Sep; 83(10):1973-1979. PubMed ID: 31391351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia.
    Wiggins BS
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e631-e640. PubMed ID: 34738550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects.
    Filippatos TD; Liontos A; Christopoulou EC; Elisaf MS
    Curr Vasc Pharmacol; 2019; 17(4):332-340. PubMed ID: 29424317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is new in lipid-lowering therapies in diabetes?
    Cheung YM; O'Brien R; Ekinci EI
    Intern Med J; 2019 Dec; 49(12):1472-1480. PubMed ID: 30887650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.
    Schiele F; Ecarnot F; Chopard R
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):88-100. PubMed ID: 28618915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications.
    Ridker PM
    Circulation; 2018 Apr; 137(17):1763-1766. PubMed ID: 29273581
    [No Abstract]   [Full Text] [Related]  

  • 27. Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?
    Orringer CE
    Trends Cardiovasc Med; 2020 Apr; 30(3):151-157. PubMed ID: 31101399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new dawn for managing dyslipidemias: The era of rna-based therapies.
    Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
    Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy.
    Brown WV
    Clin Pharmacol Ther; 2018 Aug; 104(2):269-281. PubMed ID: 29998536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dyslipidemia management update.
    Chang Y; Robidoux J
    Curr Opin Pharmacol; 2017 Apr; 33():47-55. PubMed ID: 28527325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-Density Lipoprotein Function and Dysfunction in Health and Disease.
    Chiesa ST; Charakida M
    Cardiovasc Drugs Ther; 2019 Apr; 33(2):207-219. PubMed ID: 30675710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
    Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
    Hoogeveen RC; Ballantyne CM
    Clin Chem; 2021 Jan; 67(1):143-153. PubMed ID: 33257928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future perspectives of the pharmacological management of diabetic dyslipidemia.
    Patti AM; Giglio RV; Papanas N; Rizzo M; Rizvi AA
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):129-143. PubMed ID: 30644763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoprotein(a) and Cardiovascular Diseases　- Revisited.
    Jang AY; Han SH; Sohn IS; Oh PC; Koh KK
    Circ J; 2020 May; 84(6):867-874. PubMed ID: 32336721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statin therapy for young adults: A long-term investment worth considering.
    Miedema MD; Nauffal VD; Singh A; Blankstein R
    Trends Cardiovasc Med; 2020 Jan; 30(1):48-53. PubMed ID: 30808553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.
    Page MM; Watts GF
    Diabetes Obes Metab; 2018 Feb; 20(2):270-282. PubMed ID: 28736830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-statin interventions in the prevention of cardiovascular events: Sex-based meta-analysis.
    Das A; Roy B; Bandyopadhyay D; Dasgupta S; Chakraborty S; Soudant C; Gulati M; Ray KK; Lavie CJ
    Prog Cardiovasc Dis; 2020; 63(3):228-232. PubMed ID: 32224114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lipidology update : Evidence-based treatment of dyslipidemia].
    Parhofer KG
    Internist (Berl); 2020 Jun; 61(6):573-586. PubMed ID: 32394074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.
    Ganda OP; Bhatt DL; Mason RP; Miller M; Boden WE
    J Am Coll Cardiol; 2018 Jul; 72(3):330-343. PubMed ID: 29935936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.